Premium
P3‐002: The Utility of P75NTR for Targeted Transduction of Basal Forebrain Cholinergic Neurons
Author(s) -
Antyborzec Inga Marta,
O'Leary Valerie B.,
Ovsepian Saak V.,
Dolly Oliver J.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1659
Subject(s) - basal forebrain , neurotrophin , forebrain , cholinergic neuron , biology , cholinergic , neuroscience , microbiology and biotechnology , receptor , central nervous system , biochemistry
Background: Conventional drug treatments of Alzheimer’s disease(AD) are ineffective because the therapeutic drugs often have low bioavailability, poor solubility, limited penetration across the blood-brain barrier(BBB). AD is a multi-factorial disease with several pathogenic mechanisms and pathways, therefore multifunctional nanotechnologic treatment methods may be needed to access the many molecular targets in AD.Methods:We have studies the effect of dendrimer’s on the process of brain amyloid formation based on two model peptides derived from the ABeta peptides. Results: We have found that these new polymers have a modulating effect on the process of fibre formation. Depending on their concentration, dendrimers may accelerate or retards the formation of amiloide fibres. This means they are a potentially powerful tool in the design of strategies to manage in vivo amyloid formation. Conclusions: Given their anti-ABeta amyloid properties and their crossing BBB, dendrimers can be potential new agent for early diagnosis and treatment of AD.